Clinical trials: Ethics, innovation, and how to achieve greater equity and equality
This blog was originally published on HYPER’s LinkedIn on 20 May 2023. This Clinical Trials Day, Mümün Gencoglu reflects on existing challenges to clinical trials diversity and how the role of ethics and scientific innovation can nurture a better research environment – not only today but for future generations. More information about this topic can...
Read more
How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future
The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Sarah Adam explains what we can learn from this experience when it comes to clinical trials.
Read more
How do we improve clinical trials post-pandemic?
The COVID-19 pandemic has taught us a lot and yet we can still keep learning. While the pandemic has impacted everyone, it has provided a spark for further exploration into how clinical trials should be improved globally.
Read moreCOVID-19 is modernising the way we run clinical trials: what will happen next?
This blog was originally published on Media Planet Clinical Trials Campaign on 20 May 2021. “The biopharmaceutical industry and regulatory authorities have been working to ensure clinical trials have been progressing in all diseases throughout the global pandemic. When the COVID-19 pandemic began, most of our focus went to ‘how can my family and I...
Read moreNew industry position requires submission for journal publication of all phase III clinical trials
Industry Commits to Submit for Scientific Journal Publication the Results of all its Phase III Clinical Trials The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today approved a “Joint Industry Position on the Publication of Clinical Trial Results in the Scientific Literature” 1 , previously approved by the European Federation of Pharmaceutical Industries and...
Read moreDiversity and Inclusion in Clinical Trials: Bioethical Perspective and Principles
As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient.
Read more
From big data to precision medicine: reshaping clinical trials for better patient outcomes
Artificial intelligence; machine learning; real-world data; generative biology. What do these popular phrases mean for clinical trial innovation? They mean the potential for greater understanding of diseases; better and more rapid execution of trials; more breakthrough medicines for patients. Fast-moving technological innovations can also cause uncertainty. To fully leverage these opportunities, we need all...
Read more
Clinical trials: Position papers
Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following principles: Safeguarding the privacy of patients, respecting the integrity of national regulatory systems, and maintaining incentives for investment in biomedical research.
Read moreRegulatory agilities applied to clinical trials
This policy briefing summarizes trends in reported experiences (from primary and secondary research) in the use of regulatory agilities in clinical trials observed since the start of the pandemic, reported challenges to their implementation and forward looking recommendations, whether to prepare for the next pandemic or to modernize standard normative processes to accelerate patient access to safe and effective medicines.
Read more
The Importance of Diversity & Equal Opportunities in a Healthy R&D Environment: Diversity & Inclusion in Clinical Trials
In this HYPER-IFPMA session, panellists will explore different solutions to this problem, such as the use of innovative digital tools that can improve trial design, management, and patient and site selection.
Read more